HIGHLIGHTS
- What: The authors report baseline measures of trachoma indicators for communities participating in the Azithromycin Reduction to Reach Elimination of Trachoma (ARRET), a cluster randomized trial evaluating whether mass azithromycin distribution can be discontinued in districts with TF prevalence and amp;lt;20% per the most recent trachoma impact survey. Given that the districts in this study had not received mass azithromycin distribution for 18 months, the present results support the wait and watch strategy.
- Who: Abdou Amza and collaborators from the Francis IProctor Foundation, University of California, San Francisco, California, United States of have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.